Talphera Seeks FDA Nod to Close NEPHRO Enrollment Early as Peak Sales Estimate Tops $200M
TLPH sits 51% above its 52-week low of $0.687.
Summary
Talphera submitted a briefing document asking the FDA to let it close NEPHRO CRRT enrollment as of December 31, 2026, even if fewer than the planned 70 patients are enrolled. More than 75% of the target is enrolled and the company says the blinded study already carries over 80% statistical power for the primary endpoint, so it believes the data can support a PMA filing. Updated market research lifted the nafamostat CRRT peak sales estimate above $200 million, up from prior guidance. The balance sheet is the constraint: cash and investments fell to $14.2 million at September 30 from $20.4 million at year-end 2025, against a $4.0 million quarterly net loss, and the company plans a new S-3 shelf to replace the one expiring November 30, 2026.
At the time of this announcement, TLPH was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.7M. The 52-week trading range was $0.69 to $1.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.